Hi there, Johns Creek! We've got your morning read ready! Read on to stay connected. ☀️ In today's newsletter: Boehringer Ingelheim moves HQ to Johns Creek Perry Greene apologizes for hate incident ...

New facility is expected to serve as a global hub for accelerating the development of next-generation antibody-drug ...

Coffee in hand, Johns Creek? We've got the latest town updates for you. Keep reading to stay in the loop. ☕️️ In today's ...

Boehringer Ingelheim, a biopharmaceutical firm that manufactures medicine for humans and animals, has relocated to a ...

Boehringer Ingelheim struggled to convince a three-judge panel Thursday that the US government’s drug price negotiation plan ...

CHF 27 million investment significantly bolsters Boehringer's ADC portfolio, driven by its subsidiary, NBE Therapeutics, to achieve the company’s ...

A team at the Centro Nacional de Investigaciones Cardiovasculares ... The study was supported by funding from Fundación "la Caixa", the Boehringer Ingelheim Foundation, the National Institutes ...

Credit: Tapati Rinchumrus/Shutterstock. Boehringer Ingelheim and Sweden-based Salipro Biotech have entered a research and licence agreement to expedite the development of several drug targets. The ...

On Tuesday, Boehringer Ingelheim’s Empagliflozin became off-patent in India. Major domestic drugmakers are expected to launch their generic versions soon. According to the company’s statement ...

Pictorial mark logos symbolically represent a business through an illustrative icon without using any words or letters. Some examples are the Apple, Shell, Lacoste crocodile, Twitter bird, and Tour de ...

Two years after first announcing a partnership, Boehringer Ingelheim and software firm Veeva Systems have launched Boehringer’s One Medicine platform to help the German pharma streamline its ...

(Image Credits: Pixabay) Boehringer Ingelheim’s blockbuster diabetes drug, Empagliflozin, is now off-patent in India, paving the way for domestic drugmakers to launch generic versions.